Skip to content

Join our newsletter

Donate to MPN-CC

Menu
MPN Cancer Connection logo
Your Future Matters
  • Understanding MPNs
    • General Information
    • An Overview of Myeloproliferative Neoplasms
    • What is Myelofibrosis?
    • What is Polycythemia Vera
    • What is Essential Thrombocythemia
  • Clinical Trials
    • Clinical Trial Finder
    • Search for Clinical Trials
    • Clinical Trial Acronyms and Abbreviations
    • Understanding the Phases of Clinical Trials
  • Our Impact
    • Donate
  • About
    • About Us
    • Our Founder
    • Our Mission
    • MPN-CC Team
    • Corporate Sponsors
  • Resources
    • Patient Resources
    • MPN Experts
    • Advocacy Partners
    • MPN Websites
    • Facebook Groups
    • Treatments
      • Ojjaara
      • Vonjo
      • BESREMi
      • Jakafi
      • INREBIC
  • Blog
    • Blog
  • Contact
Close Menu

MPN Clinical Trial Finder

Clinical Trial Finder

Search Results

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Study Purpose

Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity improves cognitive function in older adults and survivors of other cancers. We hypothesize that increasing physical activity can also improve cognitive function in this vulnerable population. The objective of this research is to adapt and test an evidence-based physical activity intervention, The Community Health Activities Model Program for Seniors II (CHAMPS II), in the HCT setting for adults 60 years and older. Aim 1: Adapt the CHAMPS-II manual and develop study materials using feedback from up to 10 patient/care-partner dyads who have experienced the HCT process within the last 3-6 months and HCT team members via semi-structured interviews. Aim 2: Iteratively adapt and implement CHAMPS-II intervention in three waves (2-6 patient/care-partner dyads per wave). The dyads will participate in a multi-phase, light to moderate-intensity physical activity program through Day 100 post-HCT. Aim 3: Test the preliminary effectiveness of the adapted intervention to improve cognitive function compared to a wait-list control condition (N = 34 per group) in a 2-arm, pilot randomized controlled trial. Primary and secondary outcomes will include subjective and objective cognitive function using a short battery of neuropsychological tests and a self-report questionnaire. Tertiary outcomes comprise subjective and objective measures of physical activity behavior and physical function. The RE-AIM framework will be utilized for formative and process evaluation during the adaptation process and implementation of the intervention.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 60 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Arm 1: Inclusion Criteria for Participants:

  • - age 60 years and older.
  • - have a diagnosis of hematological malignancy.
  • - have received autologous or allogeneic HCT within the prior 3-6 months.
  • - able to speak and read English.
  • - have provided written informed consent.
Exclusion Criteria for Participants:
  • - there are no exclusion criteria.
Inclusion Criteria for Participants' Care-Partner:
  • - age 19 years and older.
  • - able to speak and read English.
Exclusion Criteria for Participants' Care-Partner:
  • - there are no exclusion criteria.
Inclusion Criteria for Transplant Team Member:
  • - age 19 years and older.
  • - able to speak and read English.
Exclusion Criteria for Transplant Team Member:
  • - there are no exclusion criteria.
Arms 2 and 3: Inclusion Criteria for Participants:
  • - age 60 years and older.
  • - have a diagnosis of hematological malignancy.
  • - planned to receive an autologous or allogeneic HCT.
  • - able to walk 4 meters as part of the Short Physical Performance Battery (with or without assistance) - (In Arm 3 only): willingness to be randomized to either initiate the physical activity intervention pre-HCT or following Day 180 post-HCT, and to follow the protocol for the group to which they have been assigned.
  • - able to speak and read English.
  • - have provided written informed consent.
Exclusion Criteria for Participants:
  • - development of chest pain, severe shortness of breath, or occurrence of other safety concerns during the physical performance measures (i.e. Short Physical Performance Battery) - is not cleared to participate in exercise by a physician.
Individuals with the following current conditions/diagnoses documented in medical history will be required to provide clearance for exercise from their cardiologist:
  • - Myocardial infarctions in the past 3 months.
  • - Resting or unstable angina.
  • - Uncontrolled and/or serious arrhythmias.
  • - 3rd degree heart block.
  • - Acute congestive heart failure or ejection fraction <30% - Clinically significant aortic stenosis.
Individuals with the following conditions/diagnoses will be required to provide clearance for exercise from their surgeon: o Hip fracture, hip or knee replacement, or spinal surgery in the past 3 months.
  • - other medical, psychiatric, or behavioral factors that in the judgement of the principal investigator may interfere with study participation or the ability to follow either the intervention or the active control condition.
Inclusion Criteria for Participants' Care-Partner:
  • - age 19 years and older.
  • - able to speak and read English.
  • - able to walk 4 meters as part of the Short Physical Performance Battery (with or without assistance) - have no medical contraindications for participating in light to moderate-intensity physical activity per PI review of medical history as reported on the care-partner medical history form.
Exclusion Criteria for Participants' Care-Partner:
  • - development of chest pain, severe shortness of breath, or occurrence of other safety concerns during the physical performance measures (i.e. Short Physical Performance Battery) - is not cleared to participate in exercise by a physician.
Individuals with the following current conditions/diagnoses documented in medical history will be required to provide clearance for exercise from their cardiologist:
  • - Myocardial infarctions in the past 3 months.
  • - Resting or unstable angina.
  • - Uncontrolled and/or serious arrhythmias.
  • - 3rd degree heart block.
  • - Acute congestive heart failure or ejection fraction <30% - Clinically significant aortic stenosis.
Individuals with the following conditions/diagnoses will be required to provide clearance for exercise from their surgeon: o Hip fracture, hip or knee replacement, or spinal surgery in the past 3 months.
  • - other medical, psychiatric, or behavioral factors that in the judgement of the principal investigator may interfere with study participation or the ability to follow either the intervention or the active control condition.
Inclusion Criteria for Transplant Team Member:
  • - age 19 years and older.
  • - able to speak and read English.
Exclusion Criteria for Transplant Team Member: - there are no exclusion criteria

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04898790
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University of Nebraska
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Thuy Koll, MD
Principal Investigator Affiliation University of Nebraska
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Leukemia, Lymphoma, Multiple Myeloma, MDS, Myeloproliferative Neoplasm
Additional Details

Hematologic malignancies are diseases that primarily affect older adults, with a median age at diagnosis of 65 years. Hematopoietic cell transplantation (HCT) is a potentially curative and life-prolonging treatment for patients with hematologic malignancies. Cancer and treatment-related cognitive changes cause distress, hinder resumption of normal routine and roles, and worsen quality of life. HCT differs from the delivery of chemotherapy in other cancer settings due to the intensity of chemotherapy and severity of toxicity. Older adults undergoing HCT are at high risk for cognitive decline and pervasive cognitive deficits. Interventions to improve cognitive outcomes are needed. The prevalence and risk of cognitive decline post-HCT are greater for older adults because of a greater number of existing health conditions (i.e., vascular disease) and impaired physical and psychologic function pre-HCT that can be exacerbated by treatment and the overall HCT experience. Exercise training improves cancer-related health outcomes, including cardiorespiratory fitness, inflammation, cancer related fatigue, depressive symptoms, and sleep disturbance. There is consistent evidence showing that physical activity improves cognitive function in older adults and survivors of other cancers. Improvement in cardiorespiratory fitness, brain structure, and inflammation underlie the mechanisms of the cognitive benefits of physical activity. While untested in older adults undergoing HCT, the investigator hypothesizes that increasing physical activity can also improve cognitive function in this vulnerable population. Physical activity improves the cognitive domains most affected by cancer treatment, namely executive function and working memory. Cognitive function is an important outcome to older adults and has not been a focus of physical activity interventions in the HCT population. In addition, older adults are underrepresented in previous physical activity interventions in the HCT population. The researcher will adapt CHAMPS II, an evidence-based physical activity intervention, to the HCT setting for older adults to improve cognitive function. CHAMPS II increased physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. The program provides a foundation for application by including an instructor manual and directions for implementation. CHAMPS-II has been adapted and implemented in diverse communities using existing resources and improving contextual factors to increase physical activity for sedentary older adults. Adaptation of evidence-based interventions, such as CHAMPS-II, can result in an attenuation of effects if the core components are not maintained. However, adaptations can be made to fit the needs and priorities of the service setting, target audience, mode of delivery, and cultural context without compromising CHAMPS-II effectiveness. Through a research-practice partnership approach, the research team will help adapt the program while maintaining the core components of CHAMPS-II, develop new program materials, provide training, monitor implementation, and conduct program evaluation. The overarching goal is to enable HCT team members to implement CHAMPS-II and leverage existing organizational resources to enhance feasibility and sustainability. The research plan proposes a hybrid effectiveness-implementation design, which is a design that spans the effectiveness and implementation research to accelerate the translation of physical activity interventions into practice for older adults with cancer. This novel trial design will allow testing of the program within a randomized clinical trial methodology while observing and gathering information on implementation. The effectiveness study condition offers an ideal opportunity to examine implementation issues and plan for implementation strategies for a future study that examines both effectiveness and implementation strategies. The study will use the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework for planning and formative and process evaluation of the intervention. Formative and process evaluation provides information needed to evaluate an intervention's potential for translation into clinical practice.

Arms & Interventions

Arms

No Intervention: Feedback for Preliminary Adaptation

Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.

Experimental: Adapted CHAMPS-II intervention

All participants in Aim 2 (preliminary testing) and Aim 3 (RCT) will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members. Aim 3 participants will be randomized to either the immediate intervention (intervention then follow-up) or delayed intervention (wait period and then intervention).

Interventions

Behavioral: - CHAMPS-II adapted to adults 60+ years in HCT setting

CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of Nebraska Medical Center, Omaha, Nebraska

Status

Recruiting

Address

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Site Contact

Thuy Koll, MD

[email protected]

402-559-7519

Nearest Location

Site Contact

Thuy Koll, MD

[email protected]

402-559-7519

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

MPN CANCER CONNECTION

is a 501 (c) (3) non-profit public charity, our tax ID number is 47-4839850.

Privacy Policy

Copyright © 2024 MPN Cancer Connection,
All Rights Reserved

Follow us on Social

RSS PV Reporter News

  • Honor those who make a difference in the myeloproliferative neoplasm community: Submit a nomination to the MPN Heroes® Recognition Program today!
  • Precision Medicine in Myeloproliferative Neoplasms (MPNs): Molecular Insights and Advances
  • What Rare Disease Day Means to Me

Recent News

  • Myelofibrosis Treatment: Optimizing JAK Inhibitor Strategies in 2024
  • MPN Research 2024: Emerging Trends

JOIN OUR NEWSLETTER

There was an error. Please try again later.

Success!

  • Sponsors
  • Impact
  • Partners
  • About
  • Contact
  • NCCN Guidelines
  • Terms
  • Privacy

Site by: Kaleidoscopic